Newly-released Continuous Glucose Monitoring Device Market industry analysis report by Future Market Insights reveals that global sales of Continuous Glucose Monitoring Device Market in 2022 was held at US$ 4.9 Billion. With a CAGR of 11.9% from 2023 to 2033, the market is projected to reach a US$ 16.8 billion valuation by 2033. The Sensor component is expected to be the highest revenue-generating segment, accounting for a CAGR of nearly 11.6% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Continuous Glucose Monitoring Device Market (2023) | US$ 5.5 Billion |
| Global Continuous Glucose Monitoring Device Market (2033) | US$ 16.8 Billion |
| Global Continuous Glucose Monitoring Device Market CAGR (2023 to 2033) | 11.9% |
| USA Continuous Glucose Monitoring Device Market CAGR (2023 to 2033) | 12.5% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Continuous Glucose Monitoring Device Market industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 11.1% CAGR, wherein, countries such as the USA, UK, China, Japan and South Korea held a significant share in the global market.
The growth of the continuous blood glucose monitoring device market is being fuelled by rising diabetes awareness and the rising prevalence of diabetes among the population. By 2045, the International Diabetes Federation estimates that 700 million individuals worldwide would have diabetes.
Since obesity and the overweight population are the leading causes of diabetes, the worrisome growth in the number of overweight and obese people around the world is predicted to boost demand for continuous glucose monitoring devices.
According to the World Health Organization, over 1.9 billion people worldwide were overweight in 2016, with 650 million adults being obese. The expanding diabetic population is largely due to bad eating habits, a lack of sufficient nutrition, people's busy and demanding schedules, and a lack of physical activity. Furthermore, the growing senior population is a crucial factor driving the continuous glucose monitoring device market forward. High blood glucose levels and diabetes are common in the elderly population.
A spike in the senior population, as well as a high prevalence of diabetes, are likely to drive market expansion. By 2040, the global diabetic population is predicted to reach 642 Million, according to the International Diabetes Federation.
As a result, by 2040, one out of every 10 persons is anticipated to have diabetes, demonstrating the seriousness of the pandemic. As a result, diabetes treatment and management are projected to be a top priority for healthcare administrations and stakeholders around the world.
Increased diabetes cases are predicted to drive market growth and opportunities for continuous glucose monitoring systems, which will attract and compel several market participants to produce innovative products or product line extensions.
Principal Consultant
According to the National Centre for Biotechnology Information, continuous glucose monitoring devices outperform self-monitoring blood glucose (SMBG) devices in clinical investigations including gestational diabetes mellitus. Furthermore, the advent of technologically improved gadgets for the control of diabetes mellitus will boost product acceptance even further.
During the forecast period, Asia Pacific is expected to be the most lucrative market. Asia Pacific has a large population characterized by increased diabetic awareness, increasing awareness of the availability of continuous glucose monitoring devices, and expanding consumer healthcare spending. Moreover, throughout the projection period, increased diagnostic lab penetration in the region is likely to boost demand for continuous glucose monitoring devices.
Due to favorable government policies, countries such as China, India, South Korea, and Indonesia are drawing FDIs in the healthcare sector, which is projected to drive the growth of the continuous glucose monitoring device market in the region.
The market for continuous glucose monitoring devices in Asia Pacific is likely to develop at a significant rate over the forecast period, owing to the rising prevalence of diabetes in the region, which is expected to drive the demand for these devices. Furthermore, the tendency is projected to be aided by expanding economies, rising healthcare expenditures, and the entry of major corporations.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Due to the rising number of diabetic patients in the region, North America is likely to dominate the global market throughout the forecast period. According to the Centres for Disease Control and Prevention, 34.2 million individuals in the United States, or 10.5% of the population, had diabetes in 2020. Furthermore, over the projection period, poor diet, rising obesity rates, and government measures are projected to have a beneficial impact on these continuous monitoring products.
The market in the United kingdom is expected to reach a valuation of US$ 16.7 Billion by 2033. Growing with a CAGR of 11.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 11.2 Billion.
In Japan, the market is expected to grow at a CAGR of 10.6% from 2023 to 2033, reaching US$ 549 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 351 Million during the forecast period.
Continuous glucose monitoring devices are divided into three groups based on their components: sensors, transmitters, and receivers. In 2020, the sensors sector dominated the market, accounting for nearly 39% of total sales. From 2023 to 2033, the segment is predicted to grow at the fastest rate of 11.6%.
Sensors are the most advanced component of continuous glucose monitoring devices, consisting of a metallic filament that is injected into the fatty layer immediately beneath the skin and is thinner than a needle. The technology utilized in sensors differs slightly from that in transmitters and receivers. Glucose oxidase is used to monitor blood sugar levels in these components.
Due to increased knowledge, convenience, and ease of use, as well as rising disposable income, homecare diagnostics continues to be a market with significant opportunities. Furthermore, due to the risk of virus transmission in hospitals, COVID-19 has spurred demand for these devices in homecare diagnostics. The hospital category is predicted to grow at a high rate throughout the forecast period, owing to increased government investments in improving healthcare facilities in both developing and developed countries.
The surge in demand for Continuous glucose monitoring devices is due in part to companies' fast responses to the Covid-19 outbreak, but also to a greater awareness of the devices. The US Food and Drug Administration (FDA) has given Dexcom and Abbott permission to make their Continuous glucose monitoring devices available for use in hospitals and other healthcare facilities. The Dexcom G6 Continuous glucose monitoring devices have been provisionally approved for extended use in Canadian hospitals, according to Health Canada.
The Continuous Glucose Monitoring Device Market is highly competitive, with a handful of companies holding a significant share. The key players in the market include A. Menarini Diagnostics, Echo Therapeutics, Inc., Abbott Laboratories, Bayer AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, GlySens Incorporated, Insulet Corporation, Johnson & Johnson, LifeScan, Medtronic plc, Medtrum Technologies, Inc., Microchip Technology Inc., Micron Technology Inc., Nemaura Medical, Inc., Novo Nordisk, NXP Semiconductors, Qualcomm, Roche Diagnostics, Senseonics Holdings, Inc., STMicroelectronics, and Tandem Diabetes Care.
Some of the recent developments of key players in the Continuous Glucose Monitoring Device Market are as follows:
Similarly, recent developments related to companies offering Continuous Glucose Monitoring Device Market have been tracked by the team at Future Market Insights, which are available in the full report.
The market is valued at US$ 5.5 billion in 2023.
The market growth rate from 2023 to 2033 is expected to be 11.9%.
Abbott Laboratories, Bayer AG, and Dexcom, Inc. are key market players.
Increasing prevalence of diabetes to boost the market prospects.
From 2018 to 2022, the market registered a CAGR of 11.1%.
1. Executive Summary | Continuous Glucose Monitoring Device Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Billion) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Global Market (US$ Billion) 4.2. Market Opportunity Assessment (US$ Billion) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Global Market Growth 4.5.3. Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Analysis, 2018 to 2022 6.2. Current and Future Market Projections, 2023 to 2033 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Billion) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Billion) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Component 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Billion) Analysis By Component, 2018 to 2022 8.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Component, 2023 to 2033 8.3.1. Transmitters 8.3.2. Sensors 8.3.3. Recievers 8.4. Market Attractiveness Analysis By Component 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-use 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Billion) Analysis By End-use, 2018 to 2022 9.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By End-use, 2023 to 2033 9.3.1. Hospitals 9.3.2. Home care 9.3.3. Other end-uses 9.4. Market Attractiveness Analysis By End-use 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Billion) Analysis By Region, 2018 to 2022 10.3. Current Market Size (US$ Billion) & Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Asia Pacific 10.3.5. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 11.4. Market Value (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033 11.4.1. By Country 11.4.1.1. USA 11.4.1.2. Canada 11.4.1.3. Rest of North America 11.4.2. By Component 11.4.3. By End-use 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Component 11.5.3. By End-use 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 12.4. Market Value (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033 12.4.1. By Country 12.4.1.1. Brazil 12.4.1.2. Argentina 12.4.1.3. Rest of Latin America 12.4.2. By Component 12.4.3. By End-use 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Component 12.5.3. By End-use 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 13.4. Market Value (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033 13.4.1. By Country 13.4.1.1. Germany 13.4.1.2. France 13.4.1.3. United kingdom 13.4.1.4. Italy 13.4.1.5. Spain 13.4.1.6. Netherlands 13.4.1.7. Rest of Europe 13.4.2. By Component 13.4.3. By End-use 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Component 13.5.3. By End-use 14. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 14.4. Market Value (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033 14.4.1. By Country 14.4.1.1. China 14.4.1.2. Japan 14.4.1.3. South Korea 14.4.1.4. Rest of Asia Pacific 14.4.2. By Component 14.4.3. By End-use 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Component 14.5.3. By End-use 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 15.4. Market Value (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033 15.4.1. By Country 15.4.1.1. Saudi Arabia 15.4.1.2. South Africa 15.4.1.3. UAE 15.4.1.4. Rest of Middle East and Africa 15.4.2. By Component 15.4.3. By End-use 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Component 15.5.3. By End-use 16. Key Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.1.1. Market Value Proportion Analysis, By Key Countries 16.1.2. Global Vs. Country Growth Comparison 16.2. US Market Analysis 16.2.1. Value Proportion Analysis by Market Taxonomy 16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.2.2.1. By Component 16.2.2.2. By End-use 16.3. Canada Market Analysis 16.3.1. Value Proportion Analysis by Market Taxonomy 16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.3.2.1. By Component 16.3.2.2. By End-use 16.4. Argentina Market Analysis 16.4.1. Value Proportion Analysis by Market Taxonomy 16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.4.2.1. By Component 16.4.2.2. By End-use 16.5. Brazil Market Analysis 16.5.1. Value Proportion Analysis by Market Taxonomy 16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.5.2.1. By Component 16.5.2.2. By End-use 16.6. Germany Market Analysis 16.6.1. Value Proportion Analysis by Market Taxonomy 16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.6.2.1. By Component 16.6.2.2. By End-use 16.7. France Market Analysis 16.7.1. Value Proportion Analysis by Market Taxonomy 16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.7.2.1. By Component 16.7.2.2. By End-use 16.8. Italy Market Analysis 16.8.1. Value Proportion Analysis by Market Taxonomy 16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.8.2.1. By Component 16.8.2.2. By End-use 16.9. Spain Market Analysis 16.9.1. Value Proportion Analysis by Market Taxonomy 16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.9.2.1. By Component 16.9.2.2. By End-use 16.10. UK Market Analysis 16.10.1. Value Proportion Analysis by Market Taxonomy 16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.10.2.1. By Component 16.10.2.2. By End-use 16.11. Netherlands Market Analysis 16.11.1. Value Proportion Analysis by Market Taxonomy 16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.11.2.1. By Component 16.11.2.2. By End-use 16.12. China Market Analysis 16.12.1. Value Proportion Analysis by Market Taxonomy 16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.12.2.1. By Component 16.12.2.2. By End-use 16.13. Japan Market Analysis 16.13.1. Value Proportion Analysis by Market Taxonomy 16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.13.2.1. By Component 16.13.2.2. By End-use 16.14. South Korea Market Analysis 16.14.1. Value Proportion Analysis by Market Taxonomy 16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.14.2.1. By Component 16.14.2.2. By End-use 16.15. Saudi Arabia Market Analysis 16.15.1. Value Proportion Analysis by Market Taxonomy 16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.15.2.1. By Component 16.15.2.2. By End-use 16.16. South Africa Market Analysis 16.16.1. Value Proportion Analysis by Market Taxonomy 16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.16.2.1. By Component 16.16.2.2. By End-use 16.17. UAE Market Analysis 16.17.1. Value Proportion Analysis by Market Taxonomy 16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033 16.17.2.1. By Component 16.17.2.2. By End-use 16.17.3. Competition Landscape and Player Concentration in the Country 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Concentration 17.3. Market Share Analysis of Top Players 17.4. Market Presence Analysis 17.4.1. By Regional footprint of Players 17.4.2. Product footprint by Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. A. Menarini Diagnostics 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Sales Footprint 18.3.1.4. Strategy Overview 18.3.2. Echo Therapeutics, Inc. 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Sales Footprint 18.3.2.4. Strategy Overview 18.3.3. Abbott Laboratories 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Sales Footprint 18.3.3.4. Strategy Overview 18.3.4. Bayer AG 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Sales Footprint 18.3.4.4. Strategy Overview 18.3.5. Dexcom, Inc. 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Sales Footprint 18.3.5.4. Strategy Overview 18.3.6. F. Hoffmann-La Roche Ltd. 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Sales Footprint 18.3.6.4. Strategy Overview 18.3.7. GE Healthcare 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Sales Footprint 18.3.7.4. Strategy Overview 18.3.8. Glycens 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Sales Footprint 18.3.8.4. Strategy Overview 18.3.9. Insulet Corporation 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Sales Footprint 18.3.9.4. Strategy Overview 18.3.10. Johnson & Johnson 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Sales Footprint 18.3.10.4. Strategy Overview 18.3.11. LifeScan 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Sales Footprint 18.3.11.4. Strategy Overview 18.3.12. Medtronic plc 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Sales Footprint 18.3.12.4. Strategy Overview 18.3.13. Medtrum Technologies, Inc. 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Sales Footprint 18.3.13.4. Strategy Overview 18.3.14. Microchip Technology Inc. 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Sales Footprint 18.3.14.4. Strategy Overview 18.3.15. Micron Technology Inc. 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Sales Footprint 18.3.15.4. Strategy Overview 18.3.16. Nemaura Medical, Inc. 18.3.16.1. Overview 18.3.16.2. Product Portfolio 18.3.16.3. Sales Footprint 18.3.16.4. Strategy Overview 18.3.17. Novo Nordisk 18.3.17.1. Overview 18.3.17.2. Product Portfolio 18.3.17.3. Sales Footprint 18.3.17.4. Strategy Overview 18.3.18. NXP Semiconductors 18.3.18.1. Overview 18.3.18.2. Product Portfolio 18.3.18.3. Sales Footprint 18.3.18.4. Strategy Overview 18.3.19. Qualcomm 18.3.19.1. Overview 18.3.19.2. Product Portfolio 18.3.19.3. Sales Footprint 18.3.19.4. Strategy Overview 18.3.20. Roche Diagnostics 18.3.20.1. Overview 18.3.20.2. Product Portfolio 18.3.20.3. Sales Footprint 18.3.20.4. Strategy Overview 18.3.21. Senseonics Holdings, Inc. 18.3.21.1. Overview 18.3.21.2. Product Portfolio 18.3.21.3. Sales Footprint 18.3.21.4. Strategy Overview 18.3.22. STMicroelectronics 18.3.22.1. Overview 18.3.22.2. Product Portfolio 18.3.22.3. Sales Footprint 18.3.22.4. Strategy Overview 18.3.23. Tandem Diabetes Care 18.3.23.1. Overview 18.3.23.2. Product Portfolio 18.3.23.3. Sales Footprint 18.3.23.4. Strategy Overview 19. Assumptions and Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Continuous Glucose Monitoring Device Market
